{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:51:10Z","timestamp":1794487870036,"version":"4.9.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Influenza viruses pose a significant threat to global public health. Several influenza pandemic outbreaks have had serious economic and public health implications. Current influenza virus vaccines generally provide strain-specific protection and must be rapidly produced annually to match the circulating viruses. Developing influenza vaccines that confer protection against a broad range of viruses will have a positive impact on public health. In this study, we aimed to develop a ferritin-based influenza nanoparticle vaccine with a broad protective spectrum to enhance the immune response against diverse influenza viruses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We generated an adjuvant-free, self-assembling nanoparticle vaccine against diverse influenza A viruses. This nanoparticle vaccine displayed multi-antigen targets on the surface of\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      ferritin, which consists of the ectodomain of hemagglutinin of the H3N2 virus and three tandem highly conserved influenza M1 epitopes fused with the universal helper T-cell epitope PADRE, named HMP-NP. HMP-NPs were expressed in a soluble form in the baculovirus-insect cell system and self-assembled into homogeneous nanoparticles. Animal immunization studies showed that the HMP-NP nanovaccine elicited 4-fold higher haemagglutination inhibition (HAI) titers than inactivated influenza vaccine. And neutralization titers induced by HMP-NPs against the H3N2 virus and heterologous strains of the H1N1 and H9N2 viruses were ~8, 12.4 and 16 times higher than inactivated influenza vaccine, respectively. Meanwhile, we also observed that the number of IFN-\u03b3- and IL-4-secreting cells induced by HMP-NPs were ~2.5 times higher than inactivated influenza vaccine. Importantly, intranasal immunization with HMP-NPs, without any adjuvant, induced efficient mucosal IgA responses and conferred complete protection against the H3N2 virus, as well as partial protection against the H1N1 and H9N2 viruses and significantly reduced lung viral loads.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, our results indicated that the self-assembled nanovaccines increased the potency and breadth of the immune response against various influenza viruses and are a promising delivery platform for developing vaccines with broader protection against emerging influenza viruses and other pathogens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1519866","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T01:41:18Z","timestamp":1738287678000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Adjuvant-free, self\u2212assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses"],"prefix":"10.3389","volume":"16","author":[{"given":"Yongqiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enqi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2018.11.005","article-title":"Broadly protective influenza vaccines: design and production platforms","volume":"34","author":"Elbahesh","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz803","article-title":"Lessons from influenza pandemics of the last 100 years","volume":"70","author":"Monto","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.11.080","article-title":"Estimates of mortality associated with seasonal influenza for the European Union from the GLaMOR project","volume":"40","author":"Paget","year":"2022","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","article-title":"Toward a universal influenza virus vaccine: prospects and challenges","volume":"64","author":"Pica","year":"2013","journal-title":"Annu Rev Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12383","article-title":"An overview of the regulation of influenza vaccines in the United States","volume":"10","author":"Weir","year":"2016","journal-title":"Influenza other Resp"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080846","article-title":"The human antibody response to the influenza virus neuraminidase following infection or vaccination","volume":"9","author":"Rajendran","year":"2021","journal-title":"Vaccines"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2021.0033","article-title":"Influenza A virus hemagglutinin is produced in different disulfide-bonded states","volume":"35","author":"Fl\u00f3rido","year":"2021","journal-title":"Antioxid Redox Signal"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320524110","article-title":"Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins","volume":"110","author":"Heaton","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-120617-041310","article-title":"Is a universal influenza virus vaccine possible","volume":"71","author":"Nachbagauer","year":"2020","journal-title":"Annu Rev Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.10.003","article-title":"The quest for a universal flu vaccine: headless HA 2","volume":"18","author":"Krammer","year":"2015","journal-title":"0. Cell Host Microbe"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.07.005","article-title":"Correlates of protection against influenza infection in humans\u2013on the path to a universal vaccine","volume":"25","author":"Li","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070698","article-title":"Conserved influenza hemagglutinin, neuraminidase and matrix peptides adjuvanted with ALFQ induce broadly neutralizing antibodies","volume":"9","author":"Sei","year":"2021","journal-title":"Vaccines"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.11.6644-6654.2005","article-title":"Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2","volume":"79","author":"Zharikova","year":"2005","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242922","article-title":"Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine","volume":"43","author":"Mullarkey","year":"2013","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.029777-0","article-title":"Endogenously expressed matrix protein M1 and nucleoprotein of influenza A are efficiently presented by class I and class II major histocompatibility complexes","volume":"92","author":"Doucet","year":"2011","journal-title":"J Gen Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2017.11.018","article-title":"A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model","volume":"515","author":"Herrera-Rodriguez","year":"2018","journal-title":"Virology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01534-18","article-title":"Why are CD8 T cell epitopes of human influenza A virus conserved","volume":"93","author":"Li","year":"2019","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-020-0174-9","article-title":"Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study","volume":"5","author":"Pleguezuelos","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2612","article-title":"Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107885","article-title":"CD4(+) T cells recognize conserved influenza A epitopes through shared patterns of V-gene usage and complementary biochemical features","volume":"32","author":"Greenshields-Watson","year":"2020","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(94)80017-0","article-title":"Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides","volume":"1","author":"Alexander","year":"1994","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.11.061","article-title":"Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE)","volume":"22","author":"Alexander","year":"2004","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3905","article-title":"Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients","volume":"66","author":"Wierecky","year":"2006","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2024998118","article-title":"Intranasal vaccination with influenza HA\/GO-PEI nanoparticles provides immune protection against homo- and heterologous strains","volume":"118","author":"Dong","year":"2021","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c01829","article-title":"An intranasal multivalent epitope-based nanoparticle vaccine confers broad protection against divergent influenza viruses","volume":"17","author":"Pan","year":"2023","journal-title":"ACS Nano"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1566","article-title":"Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1192517","article-title":"Induction of broadly neutralizing H1N1 influenza antibodies by vaccination","volume":"329","author":"Wei","year":"2010","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1111497108","article-title":"Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin","volume":"108","author":"Whittle","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2006.07.009","article-title":"Adaptations of nanoscale viruses and other protein cages for medical applications","volume":"2","author":"Lee","year":"2006","journal-title":"Nanomedicine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2010.03.005","article-title":"Ferritin in the field of nanodevices","volume":"1800","author":"Yamashita","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jconrel.2019.09.002","article-title":"Ferritin drug carrier (FDC) for tumor targeting therapy","author":"He","year":"2019","journal-title":"J Control Release"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070604","article-title":"Protein-based nanoparticles as drug delivery systems","volume":"12","author":"Hong","year":"2020","journal-title":"Pharmaceutics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"Kanekiyo","year":"2013","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2018-0222","article-title":"Self-Assembling Protein Nanoparticles: implications for HIV-1 vaccine development","volume":"13","author":"Karch","year":"2018","journal-title":"Nanomedicine (Lond)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41392-021-00750-w","article-title":"The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz228","article-title":"A nanoparticle-based hepatitis C virus vaccine with enhanced potency","volume":"221","author":"Yan","year":"2020","journal-title":"J Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e2303531","DOI":"10.1002\/adhm.202303531","article-title":"Self-assembled multiepitope nanovaccine provides long-lasting cross-protection against influenza virus","volume":"13","author":"Nie","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1039\/d1nr08460g","article-title":"A self-assembling nanoparticle vaccine targeting the conserved epitope of influenza virus hemagglutinin stem elicits a cross-protective immune response","volume":"14","author":"Qiao","year":"2022","journal-title":"Nanoscale"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20173","article-title":"Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus","volume":"74","author":"Asahi-Ozaki","year":"2004","journal-title":"J Med Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/nl504798g","article-title":"Modulating antibacterial immunity via bacterial membrane-coated nanoparticles","volume":"15","author":"Gao","year":"2015","journal-title":"Nano Lett"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.002","article-title":"Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results","volume":"29","author":"Belongia","year":"2011","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1086\/595861","article-title":"Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season","volume":"199","author":"Belongia","year":"2009","journal-title":"J Infect Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz075","article-title":"Effects of influenza vaccination in the United States during the 2017-2018 influenza season","volume":"69","author":"Rolfes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis574","article-title":"Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains","volume":"55","author":"Treanor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.02.009","article-title":"Universal influenza virus vaccines and therapeutic antibodies","volume":"23","author":"Nachbagauer","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0143-6","article-title":"The human antibody response to influenza A virus infection and vaccination","volume":"19","author":"Krammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02332-17","article-title":"NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"B49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11684-017-0606-8","article-title":"Innate and adaptive T cells in influenza disease","volume":"12","author":"N\u00fcssing","year":"2018","journal-title":"Front Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e2006000","DOI":"10.1002\/smll.202006000","article-title":"Nanovaccine-based strategies to overcome challenges in the whole vaccination cascade for tumor immunotherapy","volume":"17","author":"Qin","year":"2021","journal-title":"Small"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.949779","article-title":"Refining the DC-targeting vaccination for preventing emerging infectious diseases","volume":"13","author":"Pastor","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e136653","DOI":"10.1172\/jci.insight.136653","article-title":"Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation","volume":"5","author":"Kelly","year":"2020","journal-title":"JCI Insight"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-020-0648-y","article-title":"Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B","volume":"15","author":"Wang","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12041","article-title":"Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles","volume":"7","author":"He","year":"2016","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.csbj.2015.11.001","article-title":"Self-assembling protein nanoparticles in the design of vaccines","volume":"14","author":"L\u00f3pez-Sagaseta","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1051\/jbio\/2012027","article-title":"Nanovaccines: nanocarriers for antigen delivery","volume":"206","author":"Gonzalez-Aramundiz","year":"2012","journal-title":"Biol Aujourdhui"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.03.033","article-title":"Synthetic nanovaccines for immunotherapy","volume":"263","author":"Luo","year":"2017","journal-title":"J Control Release"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1503885112","article-title":"Relationship of the quaternary structure of human secretory IgA to neutralization of influenza virus","volume":"112","author":"Suzuki","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00643-6","article-title":"Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1519866\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T01:41:21Z","timestamp":1738287681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1519866\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2025.1519866"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1519866","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1519866.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"article-number":"1519866"}}